Quick Answer
Regencell Bioscience Holdings Ltd reported Research And Development Expense of $948.3 thousand for the year ending 2025.
- Regencell Bioscience Holdings Ltd showed a decrease of -11.1% in Research And Development Expense from 2024 to 2025.
- This data is from Regencell Bioscience Holdings Ltd's annual report (Form 10-K), filed with the SEC on October 31, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Regencell Bioscience Holdings Ltd's Research And Development Expense has grown by 315.5%.
- Historical annual values: Fiscal year 2025: $948.3 thousand | Fiscal year 2024: $1.07 million | Fiscal year 2023: $1.58 million | Fiscal year 2022: $2.51 million | Fiscal year 2021: $438.3 thousand | Fiscal year 2020: $386.2 thousand | Fiscal year 2019: $228.2 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: